Hepatology International

, Volume 6, Issue 2, pp 457–467

Comparison of noninvasive models of fibrosis in chronic hepatitis B

  • S. C. Raftopoulos
  • J. George
  • M. Bourliere
  • E. Rossi
  • W. B. de Boer
  • G. P. Jeffrey
  • M. Bulsara
  • D. J. Speers
  • G. MacQuillan
  • H. L. I. Ching
  • N. Kontorinis
  • W. Cheng
  • J. Flexman
  • S. Fermoyle
  • P. Rigby
  • L. Walsh
  • D. McLeod
  • L. A. Adams
Original Article

DOI: 10.1007/s12072-011-9296-5

Cite this article as:
Raftopoulos, S.C., George, J., Bourliere, M. et al. Hepatol Int (2012) 6: 457. doi:10.1007/s12072-011-9296-5

Abstract

Background and goals

Liver fibrosis influences treatment and surveillance strategies in chronic hepatitis B (CHB). This multicenter study aimed to examine the accuracy of serum fibrosis models in CHB patients including those with low alanine aminotransferase (ALT) levels and serially in those undergoing treatment.

Method

We examined noninvasive fibrosis models [Hepascore, Fibrotest, APRI, hepatitis e antigen (HBeAg)-positive and -negative models] in 179 CHB patients who underwent liver biopsy and fibrosis assessment by METAVIR and image morphometry. Serial Hepascore measurements were assessed in 40 subjects for up to 8.7 years.

Results

Hepascore was more accurate than Fibrotest [area under the curve (AUC) 0.83 vs. 0.72, P = 0.05] and HBeAg-positive model (AUC 0.83 vs. 72, P = 0.03) for significant fibrosis but was not significantly different to APRI or HBeAg-negative scores. Fibrosis area assessed by morphometry was correlated with Hepascore (r = 0.603, P < 0.001), Fibrotest (r = 0.392, P = 0.03), and HBeAg-positive (r = 0.492, P = 0.001) scores only. Among 73 patients with an ALT <60 IU/L, noninvasive models were useful to predict fibrosis (PPV 80–90%) or exclude significant fibrosis (NPV 79–100%). Hepascore increased significantly among patients monitored without treatment and reduced among patients undergoing therapy (0.05/year ± 0.03 vs. −0.04/year ± 0.02, P = 0.007).

Conclusions

Serum fibrosis models are predictive of fibrosis in CHB and assist in identifying subjects with low–normal ALT levels for treatment.

Keywords

Hepascore APRI Fibrotest Fibrosure Image morphometry 

Copyright information

© Asian Pacific Association for the Study of the Liver 2011

Authors and Affiliations

  • S. C. Raftopoulos
    • 1
  • J. George
    • 2
  • M. Bourliere
    • 3
  • E. Rossi
    • 4
  • W. B. de Boer
    • 4
  • G. P. Jeffrey
    • 1
    • 5
  • M. Bulsara
    • 6
  • D. J. Speers
    • 4
  • G. MacQuillan
    • 1
    • 5
  • H. L. I. Ching
    • 5
  • N. Kontorinis
    • 7
  • W. Cheng
    • 7
  • J. Flexman
    • 4
  • S. Fermoyle
    • 4
  • P. Rigby
    • 8
  • L. Walsh
    • 8
  • D. McLeod
    • 9
  • L. A. Adams
    • 1
    • 5
  1. 1.Department of GastroenterologySir Charles Gairdner HospitalPerthAustralia
  2. 2.Storr Liver Unit, Westmead Millenium Institute, Westmead HospitalUniversity of SydneySydneyAustralia
  3. 3.Service d’Hépato-GastroentérologieHôpital Saint JosephMarseilleFrance
  4. 4.Department of Clinical MicrobiologyPathWest Laboratory MedicinePerthAustralia
  5. 5.School of Medicine and Pharmacology, Sir Charles Gairdner HospitalUniversity of Western AustraliaPerthAustralia
  6. 6.Department of StatisticsNotre Dame UniversityFremantleAustralia
  7. 7.Department of GastroenterologyRoyal Perth HospitalPerthAustralia
  8. 8.Center for Microscopy, Characterisation and AnalysisUniversity of Western AustraliaPerthAustralia
  9. 9.Department of Anatomical Pathology, Westmead HospitalUniversity of SydneySydneyAustralia

Personalised recommendations